These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 3530302

  • 1. Dose determinants of rebound insomnia.
    Roehrs TA, Zorick FJ, Wittig RM, Roth T.
    Br J Clin Pharmacol; 1986 Aug; 22(2):143-7. PubMed ID: 3530302
    [Abstract] [Full Text] [Related]

  • 2. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R, Rüther E, Farr I, Emilien G, Salinas E.
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [Abstract] [Full Text] [Related]

  • 3. Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam).
    Saletu B, Anderer P, Brandstätter N, Frey R, Grünberger J, Klösch G, Mandl M, Wetter T, Zeitlhofer J.
    Neuropsychobiology; 1994 Aug; 29(2):69-90. PubMed ID: 8170529
    [Abstract] [Full Text] [Related]

  • 4. Rebound insomnia and hypnotic self administration.
    Roehrs T, Merlotti L, Zorick F, Roth T.
    Psychopharmacology (Berl); 1992 Aug; 107(4):480-4. PubMed ID: 1603890
    [Abstract] [Full Text] [Related]

  • 5. Rebound insomnia: duration of use and individual differences.
    Merlotti L, Roehrs T, Zorick F, Roth T.
    J Clin Psychopharmacol; 1991 Dec; 11(6):368-73. PubMed ID: 1770156
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
    Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F.
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):117-23. PubMed ID: 11697572
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
    Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, Roth T.
    Sleep; 2011 Oct 01; 34(10):1433-42. PubMed ID: 21966075
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug 01; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 9. Minimal rebound insomnia after treatment with 10-mg zolpidem.
    Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW.
    Clin Neuropharmacol; 1997 Apr 01; 20(2):116-25. PubMed ID: 9099463
    [Abstract] [Full Text] [Related]

  • 10. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P.
    Sleep Med; 2006 Jun 01; 7(4):312-8. PubMed ID: 16709464
    [Abstract] [Full Text] [Related]

  • 11. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
    Roehrs TA, Randall S, Harris E, Maan R, Roth T.
    J Psychopharmacol; 2012 Aug 01; 26(8):1088-95. PubMed ID: 22004689
    [Abstract] [Full Text] [Related]

  • 12. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam.
    Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI.
    N Engl J Med; 1987 Sep 17; 317(12):722-8. PubMed ID: 3306380
    [Abstract] [Full Text] [Related]

  • 13. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation.
    Roehrs T, Merlotti L, Zorick F, Roth T.
    Psychopharmacology (Berl); 1992 Sep 17; 108(1-2):67-71. PubMed ID: 1410148
    [Abstract] [Full Text] [Related]

  • 14. Rebound insomnia after hypnotic withdrawal in insomniac outpatients.
    Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Rüther E.
    Eur Arch Psychiatry Clin Neurosci; 1998 Sep 17; 248(3):148-56. PubMed ID: 9728734
    [Abstract] [Full Text] [Related]

  • 15. Rebound insomnia: a critical review.
    Gillin JC, Spinweber CL, Johnson LC.
    J Clin Psychopharmacol; 1989 Jun 17; 9(3):161-72. PubMed ID: 2567741
    [Abstract] [Full Text] [Related]

  • 16. Sleep laboratory study of lormetazepam in older insomniacs.
    Vogel GW.
    Psychopharmacology Suppl; 1984 Jun 17; 1():69-78. PubMed ID: 6147842
    [Abstract] [Full Text] [Related]

  • 17. Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.
    Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL.
    Pharmacopsychiatry; 1994 Jul 17; 27(4):166-75. PubMed ID: 7972349
    [Abstract] [Full Text] [Related]

  • 18. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M, Plosker GL.
    Drugs; 2000 Aug 17; 60(2):413-45. PubMed ID: 10983740
    [Abstract] [Full Text] [Related]

  • 19. Clonazepam: sleep laboratory study of efficacy and withdrawal.
    Kales A, Manfredi RL, Vgontzas AN, Baldassano CF, Kostakos K, Kales JD.
    J Clin Psychopharmacol; 1991 Jun 17; 11(3):189-93. PubMed ID: 2066457
    [Abstract] [Full Text] [Related]

  • 20. Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study.
    Ferini Strambi L, Marelli S, Zucconi M, Galbiati A, Biggio G.
    J Neurol; 2017 Jul 17; 264(7):1362-1369. PubMed ID: 28584913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.